22.418 articles found

Group III metabotropic glutamate receptors as potential targets in the treatment of Parkinson's disease

Broadstock M.

· 2006-01-01

Neuropsychological issues in the surgical treatment of Parkinson's disease with a particular emphasis on the effects of chronic deep brain stimulation and chronic infusion of recombinant-methionyl human glial cell-line derived neurotrophic factor

Bunnage MP.

· 2006-01-01

Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.

Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.

Mov Disord · 2006-01-01

DOI: 10.1002/mds.20654PMID: 16127720

Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease.

Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA.

Mov Disord · 2006-01-01

DOI: 10.1002/mds.20666PMID: 16142776

Catatonic stupor during the course of Parkinson's disease resolved with electroconvulsive therapy.

Suzuki K, Awata S, Nakagawa K, Takano T, Matsuoka H.

Mov Disord · 2006-01-01

DOI: 10.1002/mds.20749PMID: 16250024

Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?

Denning GM, Stoll LL.

Pediatr Pulmonol · 2006-01-01

DOI: 10.1002/ppul.20338PMID: 16267824

An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.

Hirschfeld RM, Eerdekens M, Kalali AH, Canuso CM, Khan AA, Karcher K, Palumbo JM.

Int Clin Psychopharmacol · 2006-01-01

DOI: 10.1097/01.yic.0000177017.41558.fcPMID: 16317312

Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.

Pintor L, Baillès E, Valldeoriola F, Tolosa E, Martí MJ, de Pablo J.

Gen Hosp Psychiatry · 2006-01-01

DOI: 10.1016/j.genhosppsych.2005.07.005PMID: 16377367

Hallucinations in Parkinson disease in the prelevodopa era.

Fénelon G, Goetz CG, Karenberg A.

Neurology · 2006-01-01

DOI: 10.1212/01.wnl.0000191325.31068.c4PMID: 16401853

Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.

Wong LF, Goodhead L, Prat C, Mitrophanous KA, Kingsman SM, Mazarakis ND.

Hum Gene Ther · 2006-01-01

DOI: 10.1089/hum.2006.17.1PMID: 16409120

Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.

Cavazzoni PA, Berg PH, Kryzhanovskaya LA, Briggs SD, Roddy TE, Tohen M, Kane JM.

J Clin Psychiatry · 2006-01-01

DOI: 10.4088/jcp.v67n0116PMID: 16426096

Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.

Noyes K, Dick AW, Holloway RG, Parkinson Study Group.

Value Health · 2006-01-01

DOI: 10.1111/j.1524-4733.2006.00078.xPMID: 16441522